Wiedemann Andreas, Haider Shareef, Heppner Hans-Jürgen
Ev. Krankenhaus Witten gGmbH, Klinik für Urologie, Witten.
Universitat Witten, Lehrstuhl für Geriatrie, Witten.
Aktuelle Urol. 2020 Feb;51(1):48-52. doi: 10.1055/a-1069-6967. Epub 2020 Feb 4.
Muscle weakness after botulinum toxin injection into the detrusor muscle due to refractory overactive bladder is reported by approximately 10 % of patients in clinical studies. This could further aggravate the risk of falls in geriatric patients. For the first time, the potential problem of muscle weakness after urologic treatment with botulinum toxin was to be investigated by a geriatric assessment (hand grip measurement).
In a prospective study design, hand grip was measured before and three months after botulinum toxin injection into the urinary bladder in a dose of 100 - 200 MU. The measurement was performed with the usual hand grip device by pressing the pressure gauge three times with the dominant hand. Relevant muscle weakness was assumed if hand grip was reduced by more than 20 %. The measurement of 100 patients was intended.
In an interim analysis of 53 patients with an average age of 65.25 ± 13.99 years, the decrease in hand grip was + 0.00 ± 0.06 kPa or -0.13 ± 1.69 %. In patients receiving 100 MU of botulinum toxin, the decrease was +0.01 ± 0.06 kPa or -0.29 ± 1.64 %; after injection of 200 MU, it was 0.02 ± 0.06 kPa or 0.720 ± 1.77 %. The changes were neither significant for the overall population nor for the differences between the dosage groups. Therefore, the study was terminated.
The results of the hand grip measurement performed after botulinum toxin injection into the detrusor muscle demonstrated for the first time that there is no loss in hand grip as a possible indicator of muscle weakness and a risk of falls after urologic treatment with 100 MU or 200 MU. Accordingly, the botulinum toxin injection due to refractory overactive bladder seems to be safe for geriatric patients.
临床研究表明,约10%的患者在因难治性膀胱过度活动症向逼尿肌注射肉毒杆菌毒素后出现肌肉无力。这可能会进一步增加老年患者跌倒的风险。首次通过老年评估(握力测量)来研究肉毒杆菌毒素用于泌尿外科治疗后出现肌肉无力这一潜在问题。
在一项前瞻性研究设计中,对100 - 200 MU剂量膀胱内注射肉毒杆菌毒素之前和之后三个月的握力进行测量。使用常规握力装置,用优势手按压压力计三次来进行测量。如果握力下降超过20%,则假定存在相关肌肉无力。计划对100名患者进行测量。
在对平均年龄为65.25±13.99岁的53名患者进行的中期分析中,握力下降为+0.00±0.06 kPa或 -0.13±1.69%。接受100 MU肉毒杆菌毒素的患者,握力下降为+0.01±0.06 kPa或 -0.29±1.64%;注射200 MU后,为0.02±0.06 kPa或 -0.720±1.77%。这些变化在总体人群中以及剂量组之间的差异均不显著。因此,该研究终止。
向逼尿肌注射肉毒杆菌毒素后进行的握力测量结果首次表明,对于100 MU或200 MU的泌尿外科治疗,握力没有下降,这是肌肉无力和跌倒风险的一个可能指标。因此,因难治性膀胱过度活动症进行肉毒杆菌毒素注射对老年患者似乎是安全的。